Jenburkt Pharmaceuticals (524731) Q1 25/26 earnings summary

Executive summary

• Standalone unaudited financial results for the quarter ended 30th June 2025 were approved by the Board on 12th August 2025.

• The company operates exclusively in the pharmaceuticals segment.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹3,552.68 lakhs, up from ₹3,253.57 lakhs in Q1 FY25.

• Total income for the quarter was ₹3,758.39 lakhs, compared to ₹3,394.14 lakhs in the same quarter last year.

• Profit before tax for the quarter was ₹1,018.20 lakhs, up from ₹1,006.13 lakhs year-over-year.

• Profit after tax stood at ₹853.66 lakhs, compared to ₹741.60 lakhs in Q1 FY25.

• Basic and diluted EPS for the quarter was ₹17.66, up from ₹16.80 year-over-year.

Key financial ratios and metrics

• Gross margin improved as total expenses increased at a slower rate than revenue year-over-year.

• Comprehensive income for the quarter was ₹916.61 lakhs, compared to ₹896.68 lakhs in Q1 FY25.